Fig. 4.

The CRF-R1 antagonist, CP376395 prevents escalated cocaine consumption across a 24 h “binge” when administered prior to (A) social defeat stress or (B) prior to intra-VTA microinfusion of CRF; total number of cocaine infusions (0.3 mg/kg) across a 24 h shown as mean ± SEM. (A, adapted from Boyson et al., 2014; B, adapted from Leonard et al., 2017); and acute treatment with CP376395 reverses stress-escalated (C) cocaine intake during a 2 h access session or (D) cocaine-seeking responses during context-induced reinstatement (C, adapted from Han et al., 2017; D, adapted from Holly et al., 2016). *p < 0.05, **p < 0.01, ***p < 0.001 non-defeated vs. defeated; $p < 0.05, $$p < 0.01, $$$p < 0.001 vehicle-microinfusion vs. CRF-microinfusion; #p < 0.05, ##p < 0.01, ###p < 0.001 vehicle vs. CP376395.